TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22337680
Drug: Amoxicillin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1500 mg/d for 10 days)
Study: 17906193
Drug: EGCG (Teavigo)
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (Teavigo) 150 mg capsule twice daily
Study: 7845546
Drug: Atenolol plus
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol plus melatonin (1 mg at 19.30 h and 0.75 mg at 21.00 and 23.00 h)
Study: 3385910
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (160 or 320 mg daily)
Study: 28701493
Drug: Creatine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (40 g daily for up to 48 months)
Study: 26372412
Drug: Buprenorphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (20 μg/h) transdermal patch
Study: 15010695
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch
Study: 19190928
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg sublingual misoprostol tablet
Study: 19190928
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg powdery sublingual misoprostol
Study: 18650545
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/day for 4 days
Study: 17196475
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 3 days
Study: 3233185
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of RA gel
Study: 28481883
Drug: TV003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV003 vaccine (live attenuated tetravalent dengue vaccine)
Study: 21521683
Drug: Routine sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine sedative protocol (Midazolam and fentanyl) (group M)
Study: 15029143
Drug: Captopril (37.5‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5‐150 mg, average dose 72+/‐34.2 mg/day)
Study: 15029143
Drug: Eprosartan (300‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (300‐600 mg, average dose 471+/‐151 mg/day)
Study: 22926853
Drug: Placebo (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (as an add-on therapy to methylprednisolone)
Study: 20730705
Drug: Diane (35)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane (35) Diario contraceptive pill (35 μg of ethynylestradiol plus 2 mg of cyproterone acetate)
Study: 16112085
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and paclitaxel treatment in patients with valine homozygotic genotype
Study: 16112085
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and paclitaxel treatment in patients with G allele
Study: 10331327
Drug: Prelone (Muro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prelone (Muro Pharmaceuticals, Tewksbury, MA)
Study: 10331327
Drug: Prednisone 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10‐mg tablet crushed in 10 mL of cherry syrup
Study: 9112163
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 20 microliters of 0.5% timolol solution
Study: 9112163
Drug: Unilateral ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ocular administration of 20 microliters of 0.5% timolol solution
Study: 1745711
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g sugar with alcohol
Study: 1745711
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g sugar with alcohol
Study: 28967351
Drug: LSD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (100 µg)
Study: 31500679
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg) pretreatment with LSD
Study: 42487
Drug: Timolol (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (multiple doses)
Study: 42487
Drug: Timolol (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (twice-daily schedule)
Study: 42487
Drug: Timolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (single oral doses)
Study: 31771436
Drug: Ketofol (1:3)
Normalized name: Ketozole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketofol (1:3) - low-dose ketamine 0.15 mg/kg followed by propofol 0.45 mg/kg i.v.
Study: 23371895
Drug: TXA loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA loading dose of 50 mg/kg over 15 min followed by a 5 mg/kg/h maintenance infusion during surgery
Study: 23371895
Drug: Simulated loading
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated loading dose of 10 mg/kg over 15 min followed by a 5 mg/kg/h maintenance infusion
Study: 7268333
Drug: Lillehei‐Kaster (L‐K)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lillehei‐Kaster (L‐K) valves
Study: 29726739
Drug: 80-mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg ixekizumab every 2 weeks (IXEQ2W)
Study: 29726739
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etanercept (ETN) biweekly
Study: 29726739
Drug: 80-mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg ixekizumab every 4 weeks (IXEQ4W)
Study: 22690320
Drug: WGOE supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: WGOE supplementation (1500 mg/day)
Study: 19304577
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy (loose or bagged larvae)
Study: 26504153
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg)
Study: 25137428
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg)
Study: 11280847
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of zidovudine (AZT)
Study: 11280847
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of zidovudine (AZT)
Study: 1409765
Drug: Harpagophytum procumbens
Normalized name: Harpagophytum procumbens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum procumbens (Devil's Claw) - 4 capsules of 500 mg powder containing 3% total glucoiridoids daily for 21 days
Study: 2417351
Drug: Heparin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (loading dose 2,500 IU + continuous infusion of 1,800 IU/hr)
Study: 2417351
Drug: Both Org
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Org 10172 and Heparin
Study: 30324927
Drug: Oral dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexmedetomidine
Study: 16036196
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (group A)
Study: 8665534
Drug: Entacapone (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (100-800 mg)
Study: 8665534
Drug: Entacapone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (400 mg and 800 mg)
Study: 8665534
Drug: CR levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR levodopa-carbidopa without entacapone (control treatment)
Study: 6355798
Drug: Hypertransfusion (red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertransfusion (red cell transfusion to a hemoglobin value ≥ 17 gm/dl prior to each chemotherapy cycle)
Study: 26724671
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose X-ray examination (3.06 μSv)
Study: 26724671
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose X-ray examination (4.57 μSv)
Study: 26724671
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of defined criteria (dose-independent)
Study: 9883710
Drug: HCTZ (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (12.5 mg or 25 mg) alone
Study: 7976233
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 100 mg three times daily
Study: 2227221
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg three times daily
Study: 25811573
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheets for 6 months
Study: 12011552
Drug: Short (3-day)
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short (3-day) hospitalization followed by home care treatment
Study: 2185967
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (25 micrograms/h)
Study: 16290290
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin for 6 weeks
Study: 11579113
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjuvant therapy)
Study: 10506720
Drug: Carbogen inhalation
Normalized name: carbogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbogen inhalation alone
Study: 10506720
Drug: Carbogen inhalation
Normalized name: carbogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbogen inhalation with oral nicotinamide (80 mg/kg)
Study: 7554702
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 to 80 mg) taken with water in the fasting state
Study: 7554702
Drug: Alendronate with
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate with ranitidine infusion to increase gastric pH
Study: 24252703
Drug: AS03A-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-adjuvanted vaccine (3.75 μg hemagglutinin)
Study: 24252703
Drug: AS03B-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03B-adjuvanted vaccine (1.9 μg hemagglutinin, one or two doses)
Study: 21983354
Drug: All study
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study vaccines
Study: 21184272
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day (n=21)
Study: 21184272
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (n=16)
Study: 18199893
Drug: Piperaquine phosphate
Normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Piperaquine phosphate 500 mg
Study: 18199893
Drug: Piperaquine phosphate
Normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Piperaquine phosphate 750 mg
Study: 10587839
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion (4.35 mmol.kg‐1.h‐1)
Study: 29712745
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure treatment
Study: 29712745
Drug: Standard systolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systolic blood pressure treatment
Study: 21404147
Drug: Alprazolam sublingual
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam sublingual tablets (ALP-SL)
Study: 17303799
Drug: vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin (50 mg b.i.d.)
Study: 14648339
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose enalapril
Study: 11409580
Drug: amikacin 5
Normalized name: amikacin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin 5 mg/kg
Study: 11409580
Drug: amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: amikacin 15 mg/kg
Study: 3237047
Drug: 0.10 g
Normalized name: RABBIT 0.10 g in 1 mL SUBCUTANEOUS INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 g NaHCO3·kg‐1 body weight (B)
Study: 3237047
Drug: 0.15 g
Normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g NaHCO3·kg‐1 body weight (C)
Study: 3237047
Drug: 0.20 g
Normalized name: ALBUMIN HUMAN 0.20 g in 1 mL INTRAVENOUS SOLUTION [FLEXBUMIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 g NaHCO3·kg‐1 body weight (D)
Study: 23387320
Drug: Cognitive-behavioral nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral nutrition treatment
Study: 9351763
Drug: Terbutaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.25 mg)
Study: 3621618
Drug: Dopamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (1 micrograms/kg/min by i.v. infusion)
Study: 3621618
Drug: Dopamine (10(‐5)
Normalized name: dopamine hydrochloride 5 MG/ML
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (10(‐5) mol/l) in vitro
Study: 3621618
Drug: Dopamine (10(‐9)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (10(‐9) mol/l‐10(‐5) mol/l) in vitro
Study: 25782020
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy with methylprednisolone (500 mg daily intravenous for 3 days, followed by 1 mg/kg oral prednisolone for 11 days)
Study: 25782020
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral prednisolone therapy (1 mg/kg oral prednisolone for 14 days)
Study: 25782020
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (pulse therapy and traditional therapy)
Study: 26677666
Drug: Qingre Yangyin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Yangyin Recipe (QRYYR), one dose per day in two portions, once in the morning and once in the evening.
Study: 26677666
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (Metformin).
Study: 19650932
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 70 mg
Study: 15722000
Drug: Functional Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Cognitive Behavioral Therapy (fCBT)
Study: 11049785
Drug: High-dose vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vancomycin (2 g/day) combined with Saccharomyces boulardii (1 g/day for 28 days)
Study: 11049785
Drug: High-dose vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vancomycin (2 g/day) combined with placebo
Study: 15606696
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of cigarettes smoked daily
Study: 29037578
Drug: Flagellin/F1/V vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flagellin/F1/V vaccine at 6 mcg
Study: 29037578
Drug: Flagellin/F1/V vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flagellin/F1/V vaccine (all doses)
Study: 29037578
Drug: Flagellin/F1/V vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flagellin/F1/V vaccine
Study: 24756324
Drug: Diode 808-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode 808-nm laser-assisted treatment
Study: 24961183
Drug: MG +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG + MT
Study: 1718119
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (dose of 10(-9) - 10(-11) mol)
Study: 1718119
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (dose of 10(-10) mol)
Study: 7183186
Drug: Nicotine administration/cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine administration/cigarette smoking
Study: 20627197
Drug: Stannous chloride-containing
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stannous chloride-containing fluoride solution (800 ppm Sn(II), 500 ppm F, pH 4.5)
Study: 20627197
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride solution (500 ppm F, pH 4.5)
Study: 17717202
Drug: GW274150 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW274150 (90 mg)
Study: 21940420
Drug: Adjuvant given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant given 2 days after vaccine (group T5)
Study: 21940420
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent with vaccine (group T4)
Study: 8530624
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rhIGF-I, sc, twice daily
Study: 1673976
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg, daily for 2 weeks
Study: 7102709
Drug: Acyclovir and
Normalized name: Acyclovir and hydrocortisone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir and dilute steroid drops
Study: 24186848
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received repeated individual and group counseling on healthy lifestyles and guided antihypertensive therapy based on home BP measurements.
Study: 19403551
Drug: Self- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self- and manual mobilization (1 hour twice a week for 8 weeks)
Study: 17653649
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (0.64 ml) in a test meal (200 kcal per 200 ml)
Study: 15621316
Drug: Daily cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cumulative load for females
Study: 7661124
Drug: Supplemented men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented men (20 mg Fe/d)
Study: 7661124
Drug: Supplemented women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented women (20 mg Fe/d)
Study: 15914128
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 microg/DRSP 3 mg
Study: 23117775
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin
Study: 19921227
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (cannulated screw fixation)
Study: 19921227
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (short arm cast)
Study: 18940395
Drug: Plasma bFGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma bFGF immunoreactivity (bFGF‐IR) measured in pg/mL
Study: 1310385
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin and oral acyclovir prophylaxis
Study: 6436890
Drug: Nicotine 1.5
Normalized name: Nicotine 1.563 mg/hour prolonged-release transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 1.5 mg
Study: 28761118
Drug: Bortezomib (BTZ)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm)
Study: 28761118
Drug: Classical cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical cytotoxic agents prior and thalidomide after HDM (VAD arm)
Study: 28761118
Drug: Bortezomib (BTZ)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (PAD arm)
Study: 22859712
Drug: Valsartan (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (320 mg once daily)
Study: 12471537
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole daily for long-term acid suppression
Study: 10798755
Drug: Enteral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral supplementation (calorie‐dense enteral feed taken daily until transplantation)
Study: 8973689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose BCG (60 mg) and IFN alpha 2b (10, 30, 60, or 100 x 10(6) IU) given weekly for 6 weeks
Study: 1358563
Drug: Oxatomide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (60 mg/day in a single evening administration)
Study: 1358563
Drug: Disodium chromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium chromoglycate (DSCG, 2000 mg/day)
Study: 19651449
Drug: Atorvastatin 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg/day and amlodipine 10mg/day
Study: 19406402
Drug: Atorvastatin 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg/day
Study: 19651449
Drug: Atorvastatin 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg/day and placebo